曲妥珠单抗
医学
乳腺癌
动作(物理)
内科学
重症监护医学
曲妥珠单抗
癌症
药理学
风险分析(工程)
物理
量子力学
作者
Sara García-Alonso,Alberto Ocaña,Atanasio Pandiella
标识
DOI:10.1016/j.trecan.2019.12.010
摘要
The approval of ado-trastuzumab emtansine (T-DM1) for clinical use represented a turning point both in HER2-positive breast cancer treatment and antibody–drug conjugate (ADC) technology. T-DM1 has proved its value and effectiveness in advanced metastatic disease as well as in the adjuvant setting. However, its therapeutic potential extends beyond the treatment of breast cancer. Around 100 clinical trials have evaluated or are studying different aspects of T-DM1, such as its role in other HER2 malignancies, rational combinations with immunotherapy, or its function in brain metastasis. Conceptually, many lessons can be learned from this ADC. Understanding its mechanisms of action and the molecular basis underlying resistance to T-DM1 may be relevant to comprehend resistances raised to other ADCs and identify pitfalls that may be overcome.
科研通智能强力驱动
Strongly Powered by AbleSci AI